What is the rationale behind cell cycle synchronization?

It is a two-step tactic. First, a drug is administered to arrest cells in a specific phase (e.g., vincristine in the M phase). When the surviving cells simultaneously transition to the next stage, a second strike is delivered using a phase-specific agent (e.g., cytarabine in the S phase).

How can P-glycoprotein-mediated resistance be overcome?

There are two approaches: using pump inhibitors (e.g., verapamil), which is limited by their own systemic toxicity, or developing novel drugs that this efflux pump cannot recognize and extrude.

How are chemotherapy side effects managed?

Supportive care is utilized. Diuretics are administered to protect the bladder, colony-stimulating factors (filgrastim) are given for bone marrow suppression (neutropenia), and folinic acid (leucovorin rescue) or folic acid is used where applicable.

Home › Pharmacology › Antineoplastic Agents

Antineoplastic Agents

Remedia antineoplastica

For medical students2 min readUpdated 2026-10-10

Antineoplastic agents are a broad group of pharmacological agents designed to treat malignant neoplasms. Their primary target is actively dividing cells, and their main objective is to halt tumor growth or destroy the tumor with minimal possible damage to healthy tissues.

Primary TargetActively dividing cells (both tumor and healthy cells)

S PhaseAccounts for about 39% of the cell cycle time, during which DNA replication occurs

MutagenicityCytotoxic drugs themselves can induce the development of secondary tumors

Scale of the ThreatA tumor volume of 1 cm³ contains one billion cells ready for mutation

Classification by Cell Cycle Specificity

The cell life cycle often serves as the basis for therapy selection. Drugs are divided into two large groups depending on when they exert their activity:

Phase-specific agents. Target cells at a strictly defined moment of development. Most effective against tumors with a high growth fraction. For example, antimetabolites and etoposide act during the S phase (DNA replication). Taxanes, vinca alkaloids, and bleomycin act during the M phase (mitosis).
Phase-nonspecific agents. Damage cells regardless of the cycle stage, reaching them even in the resting phase ($G_0$). This group includes alkylating agents (damage DNA by attaching alkyl groups), anthracyclines, platinum compounds, and microbial-derived antitumor antibiotics.

Hormone Therapy

Some types of tumors are hormone-dependent, meaning their growth is stimulated by the body's natural hormones. Pharmacological intervention in such cases involves the use of antagonists:

Prostate gland. Prostatic tissue is stimulated by testosterone and adrenal androgens. Treatment involves antiandrogens (e.g., flutamide), which block receptors in the target tissue.
Breast. Tumor growth is stimulated by estrogens. Tamoxifen is used as an antiestrogen, blocking estrogen receptors directly in the breast tissue.

Principles of Combination Chemotherapy

Using a single drug rarely yields a sustained response, so clinicians use combinations. This achieves three goals: addressing the heterogeneous tumor cell population, delaying the development of resistance, and balancing efficacy and toxicity.

The core principle of combination design is toxicological. The regimen includes drugs that are effective on their own but exhibit different specific organ toxicities. As a result, their therapeutic effects on the tumor are additive, while side effects on healthy organs do not overlap.

Resistance and Side Effects

Tumor resistance to treatment can be primary (typical for solid tumors such as melanoma) or secondary. Secondary resistance is often associated with mutations in the TP53 gene (found in 50% of cancers), which prevents damaged cells from undergoing apoptosis. Another mechanism involves transport proteins such as P-glycoprotein (MDR1). It acts as a membrane pump, actively extruding the drug from the cytoplasm.

Cyclophosphamide damages the urinary bladder.
Doxorubicin is cardiotoxic.
Bleomycin induces pulmonary fibrosis.

Mnemonic

A classic example of combination therapy is the POMP regimen for acute lymphocytic leukemia. The acronym is easy to remember by the first letters of the drugs: Prednisone, Oncovin (vincristine), Methotrexate, Purinethol (mercaptopurine).

Frequently asked questions

What is the rationale behind cell cycle synchronization?: It is a two-step tactic. First, a drug is administered to arrest cells in a specific phase (e.g., vincristine in the M phase). When the surviving cells simultaneously transition to the next stage, a second strike is delivered using a phase-specific agent (e.g., cytarabine in the S phase).
How can P-glycoprotein-mediated resistance be overcome?: There are two approaches: using pump inhibitors (e.g., verapamil), which is limited by their own systemic toxicity, or developing novel drugs that this efflux pump cannot recognize and extrude.
How are chemotherapy side effects managed?: Supportive care is utilized. Diuretics are administered to protect the bladder, colony-stimulating factors (filgrastim) are given for bone marrow suppression (neutropenia), and folinic acid (leucovorin rescue) or folic acid is used where applicable.

Go deeper

Mechanisms of action of antimetabolites (folic acid, purine, and pyrimidine analogs)
Detailed classification of alkylating agents and platinum compounds
The role of the TP53 tumor suppressor gene in secondary drug resistance
Miscellaneous agents: enzymes, targeted therapies, and topoisomerase inhibitors
General classification: cytotoxic agents, hormones, and monoclonal antibodies